Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Imi Tami Institute For Research & Development Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single case is assigned to examiner JOHNSON, EMILY KATHARINE, who is the only examiner currently working on the company's pending matters. The prosecution is taking place within a distinct art unit, indicating a specific technical focus for this pending action. JOHNSON, EMILY KATHARINE is the busiest examiner with 1 pending action, which accounts for the entirety of the company's current pending workload.
This concentrated data suggests the portfolio is in a highly specific stage of development. Because there is only 1 pending office action, the company's immediate success depends entirely on the outcome of this one matter. The involvement of a single art unit means that the technical review is not spread across different specialized groups. Practitioners should focus their efforts on the specific requirements of the assigned examiner to ensure a favorable result for this pending case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, EMILY KATHARINE | 1 | 87.5% | +21.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19475770 | PLANTS COMPRISING BROMOFORM PRODUCTION GENES | JOHNSON, EMILY KATHARINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19475770 | PLANTS COMPRISING BROMOFORM PRODUCTION GENES | JOHNSON, EMILY KATHARINE | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19475770 | PLANTS COMPRISING BROMOFORM PRODUCTION GENES | JOHNSON, EMILY KATHARINE | 1662 | §103§112 | Non-Final OA | — | Pending | Oct 16, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImi Tami Institute For Research & Development Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emily Katharine Johnson has the most, with 1 of Imi Tami Institute For Research & Development Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
